MTSS1 Curtails Lung Adenocarcinoma Immune Evasion by Promoting AIP4-mediated PD-L1 Monoubiquitination and Lysosomal Degradation
Yuan Wang,Zhenchang Jia,Chenxi Liang,Yunfei He,Min Cong,Qiuyao Wu,Pu Tian,Dasa He,Xiang Miao,Beibei Sun,Yue Yin,Chao Peng,Feng Yao,Da Fu,Yajun Liang,Peiyuan Zhang,Hua Xiong,Guohong Hu
DOI: https://doi.org/10.1038/s41421-022-00507-x
IF: 38.079
2023-01-01
Cell Discovery
Abstract:Immune checkpoint blockade (ICB) therapy targeting PD-1/PD-L1 has shown durable clinical benefits in lung cancer. However, many patients respond poorly to ICB treatment, underscoring an incomplete understanding of PD-L1 regulation and therapy resistance. Here, we find that MTSS1 is downregulated in lung adenocarcinoma, leading to PD-L1 upregulation, impairment of CD8+ lymphocyte function, and enhanced tumor progression. MTSS1 downregulation correlates with improved ICB efficacy in patients. Mechanistically, MTSS1 interacts with the E3 ligase AIP4 for PD-L1 monoubiquitination at Lysine 263, leading to PD-L1 endocytic sorting and lysosomal degradation. In addition, EGFR-KRAS signaling in lung adenocarcinoma suppresses MTSS1 and upregulates PD-L1. More importantly, combining AIP4-targeting via the clinical antidepressant drug clomipramine and ICB treatment improves therapy response and effectively suppresses the growth of ICB-resistant tumors in immunocompetent mice and humanized mice. Overall, our study discovers an MTSS1-AIP4 axis for PD-L1 monoubiquitination and reveals a potential combinatory therapy with antidepressants and ICB.